PatientsVille.com Logo


Vemurafenib Medical Research Studies

Up-to-date List of Vemurafenib Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Vemurafenib Medical Research Studies

Rank Status Study
1 Recruiting Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Condition: Thyroid Cancer
Interventions: Drug: Vemurafenib (All Groups);   Drug: Vemurafenib (Post Surgery) - Group A + C;   Other: Post Surgery - Group B
Outcome Measures: Percent Change in ERK (Extracellular-Signal-Regulated Kinase) Phosphorylation and Tumor Size;   Objective Response Rate
2 Not yet recruiting Study of Neoadjuvant Vemurafenib for BRAF Mutant Melanoma and Palpable Lymph Node Metastasis
Condition: Melanoma
Intervention: Drug: Vemurafenib
Outcome Measures: The feasibility of treating patients with unresectable melanoma and palpable lymph node metastases that harbor the BRAF mutation with neoadjuvant Vemurafenib.;   Resectability rates post Vemurafenib therapy;   Local-regional recurrence rates after treatment with neo-adjuvant Vemurafenib.;   Time to distant metastases and Distant Metastatic Free Survival (DMFS).;   Disease Free Survival (DFS) and Overall Survival (OS).e;   Immunohistochemical correlates of tumor response.;   Safety and tolerability of Vemurafenib in the neoadjuvant setting
3 Recruiting Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
Conditions: Advanced Cancer;   Solid Tumor
Interventions: Drug: Vemurafenib;   Drug: Everolimus;   Drug: Temsirolimus
Outcome Measure: Maximum Tolerated Dose (MTD) of combination Vemurafenib
4 Recruiting Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
Condition: Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Intervention: Drug: Vemurafenib
Outcome Measures: Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D);   Toxicity Profile (dose limiting toxicities);   Concentrations of Vemurafenib in the blood found through pharmacokinetic samples;   Objective Response;   Intra-tumoral drug concentration Comparison;   Progression-free survival
5 Recruiting Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Bevacizumab
Outcome Measures: Median progression free survival;   Overall survival;   Response rates and response durations;   Serious adverse events associated with the addition of bevacizumab;   Effects of the addition of bevacizumab on tumor perfusion and immune function;   Correlate blood markers of B-RAFV600 mutation with treatment efficacy
6 Recruiting The Effects of Vemurafenib on Immunity in Patients With Melanoma
Condition: Melanoma
Intervention: Drug: Vemurafenib
Outcome Measures: Time course by which Vemurafenib increases T cell infiltration;   Activation state tumor-infiltrating T cells;   Expression of immunoinhibitory proteins;   Lysis of tumor cells;   Presence of tumor associated immune signatures;   Changes in endothelial homing receptor ligands and tumor associated chemokines;   Presence of immune/inflammatory expression pattern;   Presence of tissue-specific destruction and IFN-gamma upregulation;   IFN-gamma upregulation and TSD expression patterns relative to baseline
7 Recruiting Vemurafenib and Sorafenib in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Vemurafenib;   Drug: Sorafenib
Outcome Measures: Maximum Tolerated Dose (MTD) of Vemurafenib and Sorafenib;   Tumor Response
8 Recruiting BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Vemurafenib
Outcome Measures: efficacy of Vemurafenib;   Toxicity (safety and tolerability);   To assess the pharmacodynamics;   evaluate biomarkers
9 Recruiting Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers
Condition: Advanced Cancers
Interventions: Drug: Vemurafenib;   Drug: Cetuximab;   Drug: Irinotecan
Outcome Measure: Maximum Tolerated Dose (MTD)
10 Recruiting An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Condition: Neoplasms
Intervention: Drug: Vemurafenib
Outcome Measures: To provide continued access to Vemurafenib for eligible patients with BRAF mutation positive malignancy who were previously treated in an antecendent Vemurafenib protocol and meet criteria for continuation of Vemurafenib treatment;   Safety: Incidence of adverse events
11 Recruiting Study of Vemurafenib, Carboplatin, and Paclitaxel
Condition: Advanced Cancers
Interventions: Drug: Vemurafenib;   Drug: Carboplatin;   Drug: Paclitaxel
Outcome Measures: Maximum Tolerated Dose (MTD);   Overall Response Rate
12 Recruiting Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Condition: Melanoma
Interventions: Drug: High-dose Interferon alfa-2b;   Drug: Vemurafenib
Outcome Measures: Number of Participants with Adverse Events to determine Ph II dose;   Progression Free and overall survival (Efficacy)
13 Recruiting Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma
Condition: Melanoma
Interventions: Drug: LGX818;   Drug: LGX818+MEK162;   Drug: Vemurafenib
Outcome Measures: Progression free survival (PFS);   Overall Survival (OS);   Progression Free Survival (PFS);   Objective Response Rate (ORR);   Time To Response (TTR);   Disease Control Rate (DCR);   Duration of objective response (DOR);   Safety and tolerability of combination and LGX818;   ECOG Performance status (PS);   Time to definitive 1 point deterioration in ECOG performance status;   Pharmacokinetics of LGX818 and MEK162;   Time to definitive 10% deteriortaion in global health status (EORTC QLQC30);   Global health status (EORTC QLQC30);   Time to definitive 10% deterioration in the FACT-M melanoma subscale;   Global health status (EQ-5D)
14 Recruiting Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate;   Drug: Vemurafenib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Maximum tolerable dose of cabozantinib-s-malate in combination with Vemurafenib based on the incidence of dose-limiting toxicity (DLT) graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0.;   ORR (complete response [CR]+partial response [PR]) assessed using RECIST criteria;   DCR per RECIST version 1.1;   PFS per RECIST version 1.1
15 Recruiting A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Conditions: V600-mutated BRAF Unresectable Melanoma;   V600-mutated BRAF Metastatic Melanoma;   Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Interventions: Drug: PLX3397;   Drug: Vemurafenib
Outcome Measures: Safety-Subject incidence of adverse events;   Overall response rate - for those patients taking PLX3397 and Vemurafenib at the recommended phase 2 dose.;   Response Duration - for those patients taking PLX3397 and Vemurafenib at the recommended phase 2 dose.;   progression free survival (PFS)-for those patients taking PLX3397 and Vemurafenib at the recommended phase 2 dose.;   overall survival- for those patients taking PLX3397 and Vemurafenib at the recommended phase 2 dose.
16 Recruiting Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
Condition: Metastatic Melanoma (Carrying BRAF V600 Mutation)
Interventions: Drug: Dabrafenib;   Drug: Vemurafenib
Outcome Measures: Degree of Solar Dermatitis due to Standardized UV Exposure in Patients treated with Dabrafenib;   Degree of Solar Dermatitis due to Standardized UV Exposure in Patients treated with Dabrafenib or Vemurafenib;   Number of Participants with Adverse Events treated with dabrafenib;   Best overall response rates and progression free survival in patients treated with dabrafenib or Vemurafenib using RECIST v1.1 criteria
17 Recruiting Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Condition: Thyroid Carcinoma
Interventions: Drug: Vemurafenib;   Device: serial 124I PET/CT;   Drug: thyrotropin alpha
Outcome Measures: Response;   objective response rate (ORR);   safety
18 Recruiting The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Condition: Melanoma
Intervention: Drug: Vemurafenib
Outcome Measures: Changes in the immune cellular signature in the blood circulation;   Changes in the immune cellular signature in the tumor;   Changes in Transcriptional Profile in the blood;   Change in Transcriptional Profile in Tumor;   Changes in Dendritic Cell function in Blood;   Changes in Dendritic Cell function in Tumor;   Changes in Macrophage Function in Blood;   Changes in Macrophage Function in Tumor;   Changes in Global T cell function in Blood;   Changes in Global T cell function in Tumor;   Changes in Tumor Antigen Specific T cell Function in blood;   Changes in Histocytometry of tumor;   response to Vemurafenib treatment;   Development of Cutaneous Squamous Cell Carcinomas
19 Recruiting Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Condition: Melanoma
Interventions: Drug: XL888;   Drug: Vemurafenib
Outcome Measures: Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D);   Progression Free Survival (PFS) Rate;   Overall Survival (OS) Rate;   Overall Response Rate (ORR)
20 Not yet recruiting Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Conditions: Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Drug: Vemurafenib;   Radiation: Whole-brain radiation therapy (WBRT);   Radiation: Radiosurgery (SRS)
Outcome Measures: Maximum tolerated dose (MTD) of Vemurafenib;   Proportion with complete response;   Proportion with partial response;   Median survival;   Progression free survival based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on the brain MRI and systematic assessment by the treating physician;   Overall survival;   Local control rates of brain metastases;   Rate of developing new brain metastasis;   Response of extracranial disease

These studies may lead to new treatments and are adding insight into Vemurafenib etiology and treatment.

A major focus of Vemurafenib research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Vemurafenib